203 related articles for article (PubMed ID: 32616888)
1. Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways.
Jamal SME; Alamodi A; Wahl RU; Grada Z; Shareef MA; Hassan SY; Murad F; Hassan SL; Santourlidis S; Gomez CR; Haikel Y; Megahed M; Hassan M
Oncogene; 2020 Aug; 39(32):5468-5478. PubMed ID: 32616888
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
3. CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.
Kharouf N; Flanagan TW; Alamodi AA; Al Hmada Y; Hassan SY; Shalaby H; Santourlidis S; Hassan SL; Haikel Y; Megahed M; Brodell RT; Hassan M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334632
[TBL] [Abstract][Full Text] [Related]
4. CD133⁺ melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: significance for melanoma treatment.
El-Khattouti A; Sheehan NT; Monico J; Drummond HA; Haikel Y; Brodell RT; Megahed M; Hassan M
Cancer Lett; 2015 Feb; 357(1):83-104. PubMed ID: 25449786
[TBL] [Abstract][Full Text] [Related]
5. Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.
El-Khattouti A; Selimovic D; Haïkel Y; Megahed M; Gomez CR; Hassan M
Cancer Lett; 2014 Feb; 343(1):123-33. PubMed ID: 24080340
[TBL] [Abstract][Full Text] [Related]
6. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
7. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy.
Xi G; Li YD; Grahovac G; Rajaram V; Wadhwani N; Pundy T; Mania-Farnell B; James CD; Tomita T
Mol Cancer; 2017 Jan; 16(1):21. PubMed ID: 28137267
[TBL] [Abstract][Full Text] [Related]
10. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
Chen J; Shao R; Li F; Monteiro M; Liu JP; Xu ZP; Gu W
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1317-26. PubMed ID: 26399781
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
Calero R; Morchon E; Martinez-Argudo I; Serrano R
Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells.
Zhu Y; Yu J; Wang S; Lu R; Wu J; Jiang B
Oncol Rep; 2014 Dec; 32(6):2437-44. PubMed ID: 25230779
[TBL] [Abstract][Full Text] [Related]
13. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Niessner H; Schmitz J; Tabatabai G; Schmid AM; Calaminus C; Sinnberg T; Weide B; Eigentler TK; Garbe C; Schittek B; Quintanilla-Fend L; Bender B; Mai M; Praetorius C; Beissert S; Schackert G; Muders MH; Meinhardt M; Baretton GB; Dummer R; Flaherty K; Pichler BJ; Kulms D; Westphal D; Meier F
Clin Cancer Res; 2016 Dec; 22(23):5818-5828. PubMed ID: 27307593
[TBL] [Abstract][Full Text] [Related]
14. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133‑expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway.
Zhang X; Shao J; Li X; Cui L; Tan Z
Oncol Rep; 2019 Feb; 41(2):1067-1074. PubMed ID: 30483804
[TBL] [Abstract][Full Text] [Related]
16. [Impact of PI3K /Akt /mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin].
Ai YW; Yu HG; Yu JP; Yang Y; Li H; Hu XW; Luo HS
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):494-7. PubMed ID: 19062713
[TBL] [Abstract][Full Text] [Related]
17. IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness.
Xu WW; Li B; Zhao JF; Yang JG; Li JQ; Tsao SW; He QY; Cheung ALM
Cancer Lett; 2018 Jul; 425():88-100. PubMed ID: 29604392
[TBL] [Abstract][Full Text] [Related]
18. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
[TBL] [Abstract][Full Text] [Related]
19. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
20. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
